Dr. Michelle Erickson




Academic Degree(s)






Current Position

  • Research Biologist, VA Puget Sound Healthcare System, Seattle, WA, USA
  • Research Assistant Professor, Department of Medicine- Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, USA


Professional Experience

  • Guest Associate Editor for 2018 Named Series on “Blood-brain interfaces: roles of neuroimmunomodulation in health and disease” in Brain, Behavior, and Immunity


Education & Training

  • Ph.D., 2012 Department of Pharmacological and Physiological Sciences, Saint Louis University, Saint Louis, MO, USA
  • Postdoctoral researcher, 2012-2013, University of Washington, Seattle, WA, USA
  • Postdoctoral fellow, 2013-2016, University of Pennsylvania, Philadelphia, PA, USA



  • 2011 Young Investigator’s Educational Enhancement Travel Award, American Society for Neurochemistry conference, St. Louis, MO, USA
  • 2011 Alzheimer’s Association Travel Award, International Conference on Alzheimer’s Disease, Paris, France
  • 2014 Early Career Investigator Travel Award, Society for Neuroimmune Pharmacology conference, New Orleans, LA, USA


Research Grants

  • 2018-2020 NIEHS, ES029657-01: Ozone-induced depression, cognitive impairment, and serum amyloid A: A lung-liver-brain axis.Role:PI
  • 2018-2019 UW Alzheimer’s Disease Research Center Pilot Project Award:  Serum amyloid A as a liver-derived mediator of Alzheimer’s disease.  Role:  PI


Committee & Membership

  • 2017-2018 Scientific Affairs Committee Member, PsychoNeuroImmunology Research Society
  • 2016-present Pre- and post- doctoral training program (application reviewer) VA Puget Sound Healthcare System


Selected Publication

  • Neuroimmune Axes of the Blood-brain Barriers and Blood-brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Erickson MA and Banks WA. Pharmacol Rev. 2018 Apr;70(2):278-314.
  • Serum Amyloid A:  an ozone-induced circulating factor with potentially important functions in the lung-brain axis.  Erickson MA, Jude JA, Zhao H, Rhea EM, Salameh TS, Jester W, Pu S, Harowitz J, Nguyen N, Banks WA, Pannettieri RA, Jordan-Sciutto KL.  FASEB J. 2017 Sep;31(9):3950-3965.
  • Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. Banks WA, Gray AM, Erickson MA, Salameh TS, Damodarasamy M, Sheibani N, Meabon JS, Wing EE, Morofuji Y, Cook DG, Reed MJ. J Neuroinflammation. 2015 Nov; 12(1):223.
  • Rapid Transport of CCL11 Across the Blood-brain Barrier: Regional Variation and Importance of Blood Cells.  Erickson MA, Morofuji Y, Owen JB, Banks WA. J Pharmacol Exp Ther. 2014 Jun;349(3):497-507
  • Central and Peripheral Administration of Antisense Oligonucleotide Targeting Amyloid Precursor Protein Improves Learning and Memory and Reduces Neuroinflammatory Cytokines in Tg2576 (APPswe) Mice.  Farr SA, Erickson MA, Niehoff ML, Banks WA, Morley JE.  J Alzheimers Dis. 2014 Jan 1;40(4):1005-16.
  • Blood-brain Barrier Dysfunction as a Cause and Consequence of Alzheimer’s disease.  Erickson MA, Banks WA. J Cereb Blood Flow Metab. 2013 Oct;33(10):1500-13.